Loading...
•
Jun 30, 2024
Cardiff Oncology Q2 2024 Earnings Report
Announced financial results for the second quarter ended June 30, 2024, and provided a business update.
Key Takeaways
Cardiff Oncology reported $60.3 million in cash and cash equivalents as of June 30, 2024. The company's operating expenses were $12.7 million for the quarter, with a net loss of $11.8 million, or $0.26 per share. They believe that current cash resources are sufficient to fund operations through the end of Q3 2025.
First readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024
Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP inhibitors in high-grade serous ovarian carcinomas
Five abstracts presented at AACR provide strong scientific rationale for the clinical development of onvansertib across multiple tumor types and various combinations
Cash and equivalents of $60 million as of June 30, 2024, projected runway through the end of Q3 2025
Forward Guidance
Cardiff Oncology expects the initial readout from the first-line RAS-mut. mCRC randomized CRDF-004 trial in 2H 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...